Figure 1.
Figure 1. Relapse-free survival of the 12 responders. One of the 8 patients who achieved CR relapsed after 18 months, whereas all 4 patients who achieved either CR-RD or PR have progressed. All 15 patients treated with rituximab remained alive at the time of this report.

Relapse-free survival of the 12 responders. One of the 8 patients who achieved CR relapsed after 18 months, whereas all 4 patients who achieved either CR-RD or PR have progressed. All 15 patients treated with rituximab remained alive at the time of this report.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal